Stockscreener 앱 받기
0.848
2.42%
0.02
시장 영업 전:
.87
0.022
+2.59%
전일 마감가:
$0.828
열려 있는:
$0.829
하루 거래량:
115.17K
Relative Volume:
0.22
시가총액:
$1.95M
수익:
$502.40K
순이익/손실:
$-7.91M
주가수익비율:
-0.085
EPS:
-9.972
순현금흐름:
$-4.32M
1주 성능:
-8.91%
1개월 성능:
-32.70%
6개월 성능:
-73.92%
1년 성능:
-88.71%
1일 변동 폭
$0.7904
$0.8499
1주일 범위
$0.77
$0.9479
52주 변동 폭
$0.7015
$10.67
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
명칭
60 Degrees Pharmaceuticals Inc
전화
202-327-5422
주소
1025 CONNECTICUT AVENUE NW, WASHINGTON
SXTP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
0.848 | 1.95M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
60 Degrees Pharmaceuticals Inc 주식(SXTP)의 최신 뉴스
Palatin Technologies Inc (AMEX: PTN) Analysts Expect It Could Climb 93.76% From Current Levels. - Stocks Register
60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) Jumps 0.32 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
Titan Pharma (NASDAQ:TTNP) Stock Quotes, Forecast and News Summary - Benzinga
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates - MSN
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns Neutral Rating from HC Wainwright - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.10 Consensus Target Price from Brokerages - Defense World
60 Degrees Pharmaceuticals Enrolls First Patient in Expanded Access Clinical Study for Babesiosis Treatment - Defense World
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study - Yahoo Finance
Barclays PLC Has $109,000 Stock Holdings in DLH Holdings Corp. (NASDAQ:DLHC) - Defense World
SXTP60 Degrees Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
60 Degrees Pharmaceuticals Enrolls First Patient in - GlobeNewswire
60 Degrees Pharma Launches Breakthrough Study for Stubborn Tick Disease Treatment After 80% Success - StockTitan
🚀 Wall Street Radar: Stocks to Watch Next Week - substack.com
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - News & Insights
Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy - Streetwise Reports
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
Wainwright maintains neutral on SXTP stock after patent deal By Investing.com - Investing.com Australia
Wainwright maintains neutral on SXTP stock after patent deal - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sixty Degrees Pharmaceuticals and Tufts Medical Center - GlobeNewswire
60 Degrees Pharma Secures Exclusive Rights for Breakthrough Babesiosis Treatment with Tufts Medical Center - StockTitan
Insider Buying: Cheryl Xu Acquires 13,000 Shares of 60 Degrees P - GuruFocus.com
60 degrees pharmaceuticals director Cheryl Xu acquires $21,400 in stock - Investing.com India
60 degrees pharmaceuticals director Cheryl Xu acquires $21,400 in stock By Investing.com - Investing.com Australia
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns “Neutral” Rating from HC Wainwright - Defense World
60 Degrees Pharma shares stay Neutral amid progress on Arakoda trial - Investing.com
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital - The Manila Times
60 Degrees Pharmaceuticals launches babesiosis drug trial - Investing.com
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital - GlobeNewswire
60 Degrees Pharma Expands Promising Babesiosis Treatment Trial to Brigham & Women's Hospital - StockTitan
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: CMRX, CPIX, PCSA, CRDF, VRAR… - RTTNews
60 degrees pharmaceuticals CEO Geoffrey Dow acquires $89,755 in stock By Investing.com - Investing.com UK
60 degrees pharmaceuticals CEO Geoffrey Dow acquires $89,755 in stock - Investing.com
cbdMD (AMEX:YCBD) Stock Quotes, Forecast and News Summary - Benzinga
VSee Health CEO Reveals AI Platform's 1.5M Monthly Telehealth Encounters on Bloomberg TV | SXTP Stock News - StockTitan
VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
VSee Health CEO Reveals AI Platform's 1.5M Monthly Telehealth Encounters on Bloomberg TV | VSEE Stock News - StockTitan
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
60 Degrees & Can-Fite CEOs to Showcase Drug Pipeline on Bloomberg TV | SXTP Stock News - StockTitan
60 degrees pharmaceuticals CEO Geoffrey Dow acquires $6,367 in stock - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
60 Degrees Pharmaceuticals Reports 164% Sales Surge in Q3 2024, Driven by ARAKODA® Growth - GuruFocus.com
ARMISTICE CAPITAL, LLC Acquires New Stake in 60 Degrees Pharmace - GuruFocus.com
60 Degrees Pharmaceuticals Inc. Warrant (SXTPW) Quarterly 10-Q Report - Quartzy
HALO Stock Dips 5.77% Amid Biotech Sector Changes - GuruFocus.com
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results - Marketscreener.com
60 Degrees Pharma Reports 164% Revenue Surge, Doubles ARAKODA® Deliveries in Q3 | SXTP Stock News - StockTitan
OptiNose (OPTN) Reports Break-Even Earnings for Q3 - Nasdaq
60 Degrees Pharmaceuticals Inc (SXTP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
60 Degrees Pharmaceuticals Inc 주식 (SXTP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| XU CHERYL | Director |
Dec 12 '24 |
Buy |
1.82 |
5,000 |
9,125 |
46,078 |
| XU CHERYL | Director |
Dec 16 '24 |
Buy |
1.45 |
2,000 |
2,900 |
54,078 |
| DOW GEOFFREY S | President and CEO |
Dec 09 '24 |
Buy |
1.27 |
35,823 |
45,563 |
94,580 |
| DOW GEOFFREY S | President and CEO |
Dec 06 '24 |
Buy |
1.20 |
20,579 |
24,672 |
58,757 |
| DOW GEOFFREY S | President and CEO |
Dec 05 '24 |
Buy |
1.11 |
17,549 |
19,520 |
38,178 |
| DOW GEOFFREY S | President and CEO |
Nov 21 '24 |
Buy |
0.91 |
3,500 |
3,195 |
20,629 |
| DOW GEOFFREY S | President and CEO |
Nov 19 '24 |
Buy |
0.90 |
2,500 |
2,248 |
16,129 |
| DOW GEOFFREY S | President and CEO |
Nov 20 '24 |
Buy |
0.92 |
1,000 |
924 |
17,129 |
| XU CHERYL | Director |
Aug 27 '24 |
Buy |
1.70 |
5,000 |
8,500 |
41,078 |
| XU CHERYL | Director |
May 16 '24 |
Option Exercise |
0.22 |
2,000 |
446 |
228,934 |
4.81%
자본화:
|
볼륨(24시간):